Data from a recent study shows that more than half of patients undergoing AVR have experienced at least one post AVR PVD. Most patients will have at least one new PVD after AVR.
Abnormal sound from the valve is the only consistent physical finding; signs include holosystolic murmur, holophilic trimmings, mid-diastolic click, mid-systolic click, and post-systolic murmur. For unknown reasons, men are more likely to present with aortic valve stenosis than women.
About 1.7 million persons a year get aortic valve stenosis, making it the third most common problem with the heart in US adults. The prevalence of aortic stenosis varies from 5.4% to 10.9% across the life span. This condition worsens with age and accounts for about 60% of all cases of heart failure.
Stenosis is common in patients evaluated for aortic stenosis, but it rarely causes symptoms. The echocardiograph can be used reliably as a diagnostic tool with good correlation to the severity of the disease.
Even though satisfactory symptom control may be obtained, the long-term results (particularly in AVR) are often unsatisfactory because of recurrent worsening of symptoms or sudden deterioration.
In most cases of aortic stenosis the cause is related to high blood pressure. In about one in 200 cases, the cause is unknown (idiopathic). If systolic blood pressure is between 80 and 100 mmHg the patient should have a heart valve examination to assess the severity of the stenosis; this procedure is often followed by surgery.
There is significant variability among providers with regard to what constitutes treatment for aortic valve stenosis. In a recent study of patients with severe aortic stenosis, only 36.6% of providers cited cardiac symptoms as a primary reason for surgery. Although many patients underwent aortic valve replacements, only 16.1% of providers cited them as the primary treatment decision. For most patients, the main reason for treatment modification was a worsening level of cardiac symptoms. Other common reasons include patient demand or patient preference, as well and the presence of other concomitant disease.
These developments include use of second-generation tavr for therapeutic use, as well as the possibility that tavr could help treat other pathologies such as atrial fibrillation with the potential for improved outcomes.
[TAVI (tricuspid valve insufficiency) is a technique to treat acute severe Tricuspid aortic stenosis in both sexes and for all symptomatic and symptomatic asymptomatic patients. We know that this technique is under studies, so we will update you on their advancement]
Aortic valve stenosis is not inherited in an autosomal dominant manner. As a result, screening is strongly advised for all siblings of both aortic valve stenosis patients and those at high risk for aortic valve stenosis.
The development of new surgical techniques is an ongoing medical field but some of them appear to be better than standard surgical repairs. Especially in patients with valvular aortic stenoses, who have a high incidence of late failure and a low 5-year survival rate, the use of autologous cell therapy, gene therapy, stem cell therapy, and tissue engineering techniques may offer the best alternatives for the future. The following are some of the issues related to aortic valve stenosis: age, gender, genetic factors, size of the aortic valve, presence or absence of heart murmurs, and level of left ventricular hypertrophy.
Common side effects of tavr were headache, dyspsia, back ache, and gastrointestinal discomfort. More serious side effects of tavr were headache and back pain. Patients with valvular disease on a regular treatment regimen should be monitored closely by their doctor.